Back to Screener

Healthcare

Tibet Pharmaceuticals, Inc.(TBET)

Live Price

Offline

$0.0001

+0.00% today

Window Change

+0.00%

Window

Jun 23, 2025 โ†’ Dec 30, 2025

Market Cap
$1.49K
Revenue Growth
+40.7%
EPS Growth
+40.5%
Dividend Yield
0.0%
Partial coverage

Historical coverage is still expanding

This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.

Coverage: 133 bars ยท Jun 23, 2025 โ†’ Dec 30, 2025

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Tibet Pharmaceuticals, Inc. (TBET) is a Healthcare stock with a market cap of $1.49K and listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ†’ Dec 30, 2025). Baseline metrics include revenue growth of +40.7%, EPS growth of +40.5%, a dividend yield of 0.0%. What stands out right now is revenue +40.7%, EPS +40.5%, free cash flow -25.4% with operating margin 41.1% and ROIC 0.0%. Valuation is more restrained than many high-expectation growth names at P/E 0.0 and price/sales 0.0. Stock Foundry combines TBET price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+40.7% vs +7.6% peer median

Operating Margin

Above sector median

+41.1% vs +19.4% peer median

P/E

Below sector median

0.0 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The operating story is still moving forward

Revenue is running at +40.7% and EPS at +40.5%, with operating margin around 41.1%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

TBET

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

TBET Max Drawdown

0.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for TBET and SPY.

Calendar-year return history is still loading or unavailable.
Tibet Pharmaceuticals, Inc. logo

Company Overview

Tibet Pharmaceuticals, Inc.

Other OTC

Wanchai, HK

Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. The company, through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), develops products in China for promoting health in human respiratory, digestive, urinary, and reproductive systems. Its commercialized products include 25 Ingredients Mandrake Pill, which is used to regulate menses to treat endometritis, pelvic inflammations, and women's anemia; 15 Ingredients Gentiana Pill to treat bronchitis, emphysema, asthma, and hoarseness; 28 Ingredients Pinang Pill for treating cold waist hip pain, pus hematuria, and testis swelling; 18 Ingredients Chebulic (Myrobalan) Frusemide Pill for the treatment of kidney problems, lumbar and kidney pain, frequent urination, turbid urine, diabetes, and spermatorrhea; and Pomegranate Nichirin Pill to treat indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emission. The company also develops Xuezang Guben pill indicated for the treatment of neurasthenia, insomnia, frequent urination, nocturnal emission, and women's menopausal symptoms; Shengke I that is in Phase III clinical testing for treating type II diabetes; Shengke II, which is in Phase II clinical testing for treating impotence and premature ejaculation, prostrate disease, and memory loss; Jiuzan pill that is in Phase II clinical testing for the treatment of chronic gastroenteritis and peptic ulcers; and Antai pill, a pre-clinical stage product for treating hepatitis B. In addition, it focuses to commercialize Wupeng Pill for treating echimococosis, pandora tingling disease, diphtheria, anthrax, yellow water disease, and leprosy. The company was formerly known as Shangri-La Tibetan Pharmaceuticals, Inc. and changed its name to Tibet Pharmaceuticals Inc. in July 2010. Tibet Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Wanchai, Hong Kong.

Leadership
Hong Yu
IPO Date
Feb 10, 2023
Employees
190
Street Address
Room 1701
Mailing
Wanchai
Region
Wanchai, HK
Reporting Currency
USD
Investor Line
852 9798 5569
Last Updated
May 5, 2026
ISIN: VGG886151023
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
0.0
EV/EBITDA
โ€”
Price/Sales
0.0
Price/Book
0.0

Growth

Revenue
+40.7%
EPS
+40.5%
Free Cash Flow
-25.4%

Profitability

Gross Margin
50.0%
Operating Margin
41.1%
Net Margin
40.6%
ROE
77.3%
ROIC
0.0%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
4.48

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.